China Registration Study in Patients With Skin Infections

A Phase 3, Multicentre, Randomised, Investigator-blinded, Parallel-groupStudy of the Safety and Efficacy of Intravenous Daptomycin (Cubicin®)Compared With That of Comparator (Vancomycin or Vancomycin Followed by Semi-synthetic Penicillin-cloxacillin) in the Treatment of Chinese Subjects With cSSSI

The objectives of this study is to evaluate the Safety and Efficacy of Intravenous Daptomycin (Cubicin®)Compared with that of Comparator (Vancomycin or Vancomycin Followed by Semi-synthetic Penicillin-cloxacillin) in the Treatment of Chinese Subjects with Complicated Bacterial Skin and Skin Structure Infection due to Gram-Positive Pathogens.

Study Overview

• Status: Completed
• Conditions: Skin Diseases; Infectious
• Intervention / Treatment: Drug: Daptomycin; Drug: Vancomycin

• Study Type: Interventional
• Enrollment (Actual): 265
• Phase: Phase 3

Contacts and Locations

Study Locations

• China
  • Chongqing, China
    • Research site
  • Dalian, China
    • Research site
  • Hangzhou, China
    • Research site
  • Qingdao, China
    • Research site
  • Beijing
    • Beijing, Beijing, China
      • Research site
  • Guangdong
    • Guangzhou, Guangdong, China
      • Research site
  • Hubei
    • Wuhan, Hubei, China
      • Research site
  • Hunan
    • Changsha, Hunan, China
      • Research site
  • Jiangsu
    • Nanjing, Jiangsu, China
      • Research site
    • Suzhou, Jiangsu, China
      • Research site
  • Liaoning
    • Shenyang, Liaoning, China
      • Research site
  • Shanghai
    • Shanghai, Shanghai, China
      • Research site
  • Sichuan
    • Chengdu, Sichuan, China
      • Research site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Provision of inform consent
• A diagnosis of of complicated skin and skin structure infection known or suspected to be due to Gram-positive bacteria
• Diagnosis of bacterial skin and skin structure infection in the presence of some complicating factor, including infections involving deeper soft tissue or requiring surgical intervention, a pre-existing lesion or underlying condition affect healing

Exclusion Criteria:

• Subjects known to have any bloodstream infection (including bloodstream infection caused by S. aureus). Subjects whose baseline blood cultures are positive for any clinically pathogenic organism ( including S. aureus ) should be discontinued from study
• Minor or superficial skin infections, Infected "decubitus"ulcer, Perirectal abscess, Hidradenitis suppurativa, Myositis, Multiple infected ulcers at distant sites, Infected burn wounds of a large area,
• Conditions requiring surgery that in and of itself would cure the infection or remove the infected site (eg, amputation)
• Conditions requiring emergent surgical intervention at the site of infection (eg, progressive necrotizing infections)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: AZ drug; Daptomycin	Drug: Daptomycin; 4mg/kg IV ; Q 24 hr (once every 24 hours); Other Names: Cubicin®
Active Comparator: Comparator; Vancomycin or Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin	Drug: Vancomycin; Vancomycin - 1g per 12 hrs, for 7-14 days Or switch to Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin: - 1 g every 6 hours or 2 g every 8 hours

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of Erythrocyte Volume Fraction(Percentage of Erythrocyte Volume in Total Volume of Blood)	Erythrocyte volume fraction means under certain conditions, after centrifugation pressing, the percentage of erythrocyte volume in the total volume of blood	baseline to TOC(test of cure), for up to 4 weeks
Change in Creatinine Clearance		baseline to TOC(test of cure), for up to 4 weeks
Change in Serum Total Creatine Phosphokinase (CPK)		baseline to TOC(test of cure), for up to 4 weeks
Change in Urine pH		baseline to TOC(test of cure), for up to 4 weeks
Shift in ECG	percentage of patients who were primarily tested as normal ECG at baseline and changed into abnormal ECG at TOC visit in all the patients with normal ECG at baseline	baseline to TOC(test of cure), for up to 4 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Blinded Investigator's Assessement of Clinical Response at TOC(Test of Cure)	The percentage of patients who were cured or clinically improved in the clinical evaluable (CE) population of each arm at TOC visit was analyzed. CE population includes all the patients with no significant deviation from study protocol in full analysis set population, and meetting the following specific criteria: 1.receiving randomly dispensed study treatment at appropriate time(with a compliance of at least 80% or 4 days [3 days for patients evaluated as treatment failure]). 2.without the administration of potentially confounding non-investigational antibiotics (using one potentially effective non-investigational antibiotic for the treatment of primary infection due to other reasons than lack of efficacy from Day 1 to TOC [for systemicadministration of non-glycopeptides, >1 calendar day]). 3.meeting the study inclusion/exclusion criteria 4.necessary clinical evaluation performed (evaluation for effectiveness at TOC visit, except for the condition confirmed as clinically ineffective)	baseline and TOC, for up to 4 weeks
Blinded Investigator's Assessement of Clinical Response at EOT(End of Therapy)	The percentage of patients who were cured or clinically improved in the clinical evaluable (CE) population at EOT visit was analyzed. CE population includes all the patients with no significant deviation from study protocol in full analysis set population, and meetting the following specific criteria: 1.receiving randomly dispensed study treatment at appropriate time(with a compliance of at least 80% or 4 days [3 days for patients evaluated as treatment failure]). 2.without the administration of potentially confounding non-investigational antibiotics (using one potentially effective non-investigational antibiotic for the treatment of primary infection due to other reasons than lack of efficacy from Day 1 to TOC [for systemicadministration of non-glycopeptides, >1 calendar day]). 3.meeting the study inclusion/exclusion criteria 4.necessary clinical evaluation performed (evaluation for effectiveness at TOC visit, except for the condition confirmed as clinically ineffective)	baseline and EOT(end of therapy), for up to 2 weeks
Microbiological Response at TOC(Test of Cure)	The microbiological response rate (removal or presumed removal) in ME(microbiological evaluable) population of daptomycin group and comparator group at TOC visit was analyzed. ME population includes all the patients with Gram-positive pathogenic bacteria isolated at baseline in CE population. Microbiological response rate means the percentage of strains which were removed or presumably removed at TOC visit in all the strains isolated from ME population at baseline.	baseline and TOC, for up to 4 weeks
Microbiological Response at EOT(End of Therapy)	The microbiological response rate (removal or presumed removal) in ME(microbiological evaluable) population of daptomycin group and comparator group at EOT visit was analyzed. ME population includes all the patients with Gram-positive pathogenic bacteria isolated at baseline in CE population. Microbiological response rate means the percentage of strains which were removed or presumably removed at EOT visit in all the strains isolated from ME population at baseline.	baseline and EOT, for up to 2 weeks
Per-pathogen(Methicillin Resistant Staphylococcus Aureus) Clinical Response at TOC(Test of Cure)	This is the comparison of clinical efficacy by methicillin resistant staphylococcus aureus(MRSA) between the two groups. As the analysis was performed by specific pathogen in ME population and clinical efficacy was compared meanwhile, the clinical evaluation was based on the number of cases under the category of specific pathogen rather than the number of strains. Percentage of patients who were cured or improved at TOC visit in the patients who were identified with MRSA infection at baseline of both groups.	baseline and TOC, for up to 4 weeks
Per-pathogen(Methicillin Sensitive Staphylococcus Aureus) Clinical Response at TOC	This is the comparison of clinical efficacy by methicillin sensitive staphylococcus aureus(MSSA) between the two groups. As the analysis was performed by specific pathogen in ME population and clinical efficacy was compared meanwhile, the clinical evaluation was based on the number of cases under the category of specific pathogen rather than the number of strains. Percentage of patients who were cured or improved at TOC visit in the patients who were identified with MSSA infection at baseline of both groups.	baseline and TOC(test of cure), for up to 4 weeks
Per-pathogen(Staphylococcus Aureus) Microbiological Response at TOC	This is the comparison of clinical efficacy by staphylococcus aureus between the two groups. As the analysis was performed by specific pathogen in ME population and clinical efficacy was compared meanwhile, the clinical evaluation was based on the number of cases under the category of specific pathogen rather than the number of strains. Percentage of patients who were cured or improved at TOC visit in the patients who were identified with staphylococcus aureus infection at baseline of both groups.	baseline and TOC(test of cure), for up to 4 weeks

Collaborators and Investigators

• Sponsor: AstraZeneca
• Investigators: Study Director: Karen Atkin, AstraZeneca; Principal Investigator: Zhang Yingyuan, Prof., Antibiotics Institute, Huashan Hospital Affilicated to Fudan University

Publications and helpful links

Helpful Links

• Related Info
• CSR-D1790C00003.pdf

Study record dates

Study Major Dates

• Study Start: September 1, 2008
• Primary Completion (Actual): September 1, 2010
• Study Completion (Actual): September 1, 2010

Study Registration Dates

• First Submitted: October 9, 2008
• First Submitted That Met QC Criteria: October 14, 2008
• First Posted (Estimate): October 15, 2008

Study Record Updates

• Last Update Posted (Estimate): March 9, 2015
• Last Update Submitted That Met QC Criteria: February 23, 2015
• Last Verified: February 1, 2015

More Information

Terms related to this study

• Keywords: Skin Infections; Complicated Bacterial Skin and Skin Structure Infection due to Gram-positive Pathogens
• Additional Relevant MeSH Terms: Skin Diseases; Anti-Infective Agents; Anti-Bacterial Agents; Vancomycin; Daptomycin
• Other Study ID Numbers: D1790C00003